Close Menu

NEW YORK – Promega said on Tuesday that it has received CE marking for its OncoMate MSI Dx Analysis System, allowing it to make the test available as an in vitro diagnostic medical device in Europe.

OncoMate MSI is a PCR-based assay that measures microsatellite instability status in tissue samples from solid tumors. According to Promega, the kit offers high analytical sensitivity and specificity with a short turnaround time.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.